Walter Alexander Wohlgemuth
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Walter Alexander Wohlgemuth has a total of 37 co-authors. Here are the top co-authors by number of shared publications:
- Andreas Deistung
University Clinic and Outpatient Clinic for Radiology, Department for Radiation Medicine, University Hospital Halle (Saale), University Medicine Halle, Halle (Saale), Germany
3 shared publications Beatrix Cucuruz
3 shared publications- Alexander Gussew
University Clinic and Outpatient Clinic for Radiology University Hospital Halle (Saale) Halle (Saale) Germany
2 shared publications - Andreas Posa
University Clinic and Outpatient Clinic for Radiology, Martin Luther University Halle-Wittenberg, Ernst-Grube-Straße 40, 06120 Halle (Saale), Germany
2 shared publications - Anne Slawig
Department of Diagnostic and Interventional Radiology, University of Würzburg, Würzburg, Germany
2 shared publications - Christina Loberg
Department of Diagnostic and Interventional Radiology, University Hospital Düsseldorf, Medical Faculty of Heinrich Heine University Düsseldorf, 40225 Düsseldorf, Germany
2 shared publications
Latest Publications
- 19 May 2026
- Published by Hogrefe Publishing Group in Vasa
Trametinib for the treatment of advanced stage patients with arterio-venous malformations
Summary: Background: Arterio-venous malformations (AVMs) may lead to vessel aneurysms and thus to life-threatening bleeding or malperfusion of the extremities, causing recurrent ulceration. Possible therapies are embolisation and/or resection. This study investigates treatment options for patients with AVM Schobinger stage III and IV for whom embolisation and resection are no longer possible and medical treatment with trametinib, a mitogen-activated protein kinase inhibitor (MEK) was performed. Patients and methods: As part of the German guideline development process for the diagnosis and treatment of vascular malformations (AWMF register number 003-007), a systematic literature search was performed using a professional service provider, followed by a retrospective, exploratory analysis based on a consecutive local registry at an interdisciplinary tertiary care center for vascular anomalies. All patients with AVM Schobinger stage IIII – IV were included. Results: Of the 559 reports on specific medications for vascular malformations, only 4 (0.7%) included treatment with trametinib, and only 2 (0.4%) of them addressed its use in AVMs showing reduced blood inflow in the malformation or volume reduction. In our case series of 99 consecutive patients with AVM Schobinger stage III–IV, nine were treated with trametinib. Out of them, 6/9 (66%) had ulceration. 1/6 (20% of the patients with ulceration died, one patient required major amputation, and 4 (60%) were healed without recurrence through treatment. Three patients with chronic pain showed reduced symptoms without requiring additional analgesics. Conclusions: The single cases found in the literature and our small case series suggest that MEK1-inhibitors, such as trametinib, are an option for treating AVM Schobinger stage III – IV. Further large-scale studies are required to confirm these initial observations and to fully explore the potential of MEK1-inhibitors.
- 19 May 2026
- Published by Hogrefe Publishing Group in Vasa
Trametinib for the treatment of advanced stage patients with arterio-venous malformations
Summary: Background: Arterio-venous malformations (AVMs) may lead to vessel aneurysms and thus to life-threatening bleeding or malperfusion of the extremities, causing recurrent ulceration. Possible therapies are embolisation and/or resection. This study investigates treatment options for patients with AVM Schobinger stage III and IV for whom embolisation and resection are no longer possible and medical treatment with trametinib, a mitogen-activated protein kinase inhibitor (MEK) was performed. Patients and methods: As part of the German guideline development process for the diagnosis and treatment of vascular malformations (AWMF register number 003-007), a systematic literature search was performed using a professional service provider, followed by a retrospective, exploratory analysis based on a consecutive local registry at an interdisciplinary tertiary care center for vascular anomalies. All patients with AVM Schobinger stage IIII – IV were included. Results: Of the 559 reports on specific medications for vascular malformations, only 4 (0.7%) included treatment with trametinib, and only 2 (0.4%) of them addressed its use in AVMs showing reduced blood inflow in the malformation or volume reduction. In our case series of 99 consecutive patients with AVM Schobinger stage III–IV, nine were treated with trametinib. Out of them, 6/9 (66%) had ulceration. 1/6 (20% of the patients with ulceration died, one patient required major amputation, and 4 (60%) were healed without recurrence through treatment. Three patients with chronic pain showed reduced symptoms without requiring additional analgesics. Conclusions: The single cases found in the literature and our small case series suggest that MEK1-inhibitors, such as trametinib, are an option for treating AVM Schobinger stage III – IV. Further large-scale studies are required to confirm these initial observations and to fully explore the potential of MEK1-inhibitors.
- 1 January 2026
- Published by Georg Thieme Verlag KG
Klippel-Trénaunay-Syndrom
- 1 January 2026
- Published by Georg Thieme Verlag KG
Venöse Malformationen
- 1 January 2026
- Published by Georg Thieme Verlag KG
Invasive Therapie von Hämangiomen
- Open Access
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
Multimodal Diagnostics in Post-COVID: protocol of a matched-pair case-control study (Preprint)
- 8 December 2025
- Published by JMIR Publications Inc. in JMIR Research Protocols
Open AccessMultimodal Diagnostics in Post-COVID: protocol of a matched-pair case-control study (Preprint)
- Open Access
- 14 October 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (2) , 693-705
Fast 3D UTE in vivo T 1 and T2*$ {\mathrm{T}}_2^{\ast } $ mapping of fast relaxing knee tissues at 3 TPurpose: UTE MR imaging captures quantitative signals in fast‐relaxing tissues, enabling anatomical visualization and quantitative assessment of T 1 and relaxation times. However, the clinical application of quantitative UTE MRI is limited by long acquisition times. Therefore, this study introduces a novel UTE‐based method for T 1 and mapping, achieving submillimeter resolution in less than 10 min. Theory and Methods: The method employs a dual‐echo acquisition for fast mapping, augmented by an additional acquisition with different T 1 weighting. This second scan enables the computation of signal ratios between scans with different T 1 ‐weighting. These measured signal ratios are then compared to a lookup table containing distinct ratios, corresponding to discrete T 1 values. The approach was validated in phantom solutions mimicking various T 1 and times and applied in vivo to quantify relaxation times across different knee tissue compartments in healthy individuals. Results: The method demonstrated its reliability for T 1 and quantification in rapidly relaxing tissues (1–11 ms). However, it exhibited a tendency to underestimate in skeletal muscle. This limitation arises from the chosen TEs being inadequate to capture slow signal decays. In accordance with the findings of preceding studies, this in vivo study identified three distinct T 1 categories of tissue characterized by short (adipose tissue), moderate (ligaments, tendons, and menisci), and long (skeletal muscle) T 1 values. Conclusion: The presented technique for combined T 1 and mapping enables relaxometry in rapidly relaxing tissues, indicating potential for advanced tissue characterization in clinical settings.
- 14 October 2025
- Published by Wiley in Magnetic Resonance in Medicine
- Vol. 95 (2) , 693-705
Open AccessFast 3D UTE in vivo T 1 and T2*$ {\mathrm{T}}_2^{\ast } $ mapping of fast relaxing knee tissues at 3 TPurpose: UTE MR imaging captures quantitative signals in fast‐relaxing tissues, enabling anatomical visualization and quantitative assessment of T 1 and relaxation times. However, the clinical application of quantitative UTE MRI is limited by long acquisition times. Therefore, this study introduces a novel UTE‐based method for T 1 and mapping, achieving submillimeter resolution in less than 10 min. Theory and Methods: The method employs a dual‐echo acquisition for fast mapping, augmented by an additional acquisition with different T 1 weighting. This second scan enables the computation of signal ratios between scans with different T 1 ‐weighting. These measured signal ratios are then compared to a lookup table containing distinct ratios, corresponding to discrete T 1 values. The approach was validated in phantom solutions mimicking various T 1 and times and applied in vivo to quantify relaxation times across different knee tissue compartments in healthy individuals. Results: The method demonstrated its reliability for T 1 and quantification in rapidly relaxing tissues (1–11 ms). However, it exhibited a tendency to underestimate in skeletal muscle. This limitation arises from the chosen TEs being inadequate to capture slow signal decays. In accordance with the findings of preceding studies, this in vivo study identified three distinct T 1 categories of tissue characterized by short (adipose tissue), moderate (ligaments, tendons, and menisci), and long (skeletal muscle) T 1 values. Conclusion: The presented technique for combined T 1 and mapping enables relaxometry in rapidly relaxing tissues, indicating potential for advanced tissue characterization in clinical settings.
- Open Access
- 1 January 2025
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2025 (1)
Bilateral Cerebral Calcifications in Secondary Fahr’s Syndrome
Fahr’s syndrome is a rare, slowly progressive neurodegenerative disorder characterised by bilateral cerebral calcifications, mostly in the basal ganglia. These cerebral calcifications are composed of calcium and phosphate and are the result of disturbances in calcium‐phosphate homeostasis. The clinical manifestations include neurological, neurocognitive and psychiatric symptoms. This article describes three rare cases of pronounced bilateral cerebral calcifications. All three patients were admitted to the hospital due to a first‐time epileptic seizure. In all three cases, laboratory tests showed significant hypocalcaemia, and cerebral computed tomography showed pronounced bilateral cerebral calcifications in various brain areas. After calcium substitution and anticonvulsant treatment, the patients returned to their prehospital condition and were discharged home seizure free. The aim of this article is to highlight the clinical importance of long‐term follow‐up biochemical laboratory testing and neurocranial imaging in high‐risk patients (e.g., after thyroidectomy) to prevent avoidable neurological and psychiatric complications through pharmaceutical and nutritional substitution therapy.
- 1 January 2025
- Published by Wiley in Case Reports in Neurological Medicine
- Vol. 2025 (1)
Open AccessBilateral Cerebral Calcifications in Secondary Fahr’s Syndrome
Fahr’s syndrome is a rare, slowly progressive neurodegenerative disorder characterised by bilateral cerebral calcifications, mostly in the basal ganglia. These cerebral calcifications are composed of calcium and phosphate and are the result of disturbances in calcium‐phosphate homeostasis. The clinical manifestations include neurological, neurocognitive and psychiatric symptoms. This article describes three rare cases of pronounced bilateral cerebral calcifications. All three patients were admitted to the hospital due to a first‐time epileptic seizure. In all three cases, laboratory tests showed significant hypocalcaemia, and cerebral computed tomography showed pronounced bilateral cerebral calcifications in various brain areas. After calcium substitution and anticonvulsant treatment, the patients returned to their prehospital condition and were discharged home seizure free. The aim of this article is to highlight the clinical importance of long‐term follow‐up biochemical laboratory testing and neurocranial imaging in high‐risk patients (e.g., after thyroidectomy) to prevent avoidable neurological and psychiatric complications through pharmaceutical and nutritional substitution therapy.